Drugs / KRN330
last change Oct 2012 re-read 2 minutes ago

KRN330

Monoclonal antibody targets GPA33

Developed for
colorectal cancer
Investigated by
Kyowa Kirin, Inc. · Kyowa Hakko Kirin Pharma, Inc.

Trials 2 · a red edge is where a trial was stopped

200720082009201020112012201320142015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT00575562 Jun 2007 → Jan 2010 colorectal cancer Kyowa Kirin, Inc. Completed No outcome recorded
Phase 1/21 trial
Phase 1/2 NCT00838578 Mar 2009 → Jul 2012 colorectal cancer Kyowa Kirin, Inc. Terminated No outcome recorded

Evidence & citations 3 cited values

Every value below carries the sentence it was read from. 3 sources stand behind the page.

FieldValueCited text
Known as KRN330 ClinicalTrials.gov intervention name — accepted as the source's own label NCT00575562
1

NCT00838578

Modality Monoclonal antibody “Phase I Study of KRN330 Monoclonal Antibody in Patients With Colorectal Cancer” NCT00575562
Target GPA33 “Cell surface A33 antigen binding agent” CHEMBL2109293